^
    Back
    Association details:
    Biomarker:KRAS exon 2 mutation
    Cancer:Colorectal Cancer
    Drug:Koselugo (selumetinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Cancer Chemother Pharmacol
    Title:

    Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer

    Excerpt:
    Patients with K-RAS mutated colorectal cancer, progressing on first-line oxaliplatin-based chemotherapy with bevacizumab, were eligible for this multicenter open-label phase I/II trial...All had K-RAS exon 2 mutated tumors...Three patients (9.7 %) had partial response. Sixteen patients (51.6 %) had stable disease for ≥4 weeks, including three >1 year.
    DOI:
    0.1007/s00280-014-2609-3